Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task

Guoying Ni; Lu Zhang; Xiaodan Yang; Hejie Li; Bowei Ma; Shelley F Walton; Xiaolian Wu; Jianwei Yuan; Tianfang Wang; Xiao Song Liu

doi:10.1080/21645515.2020.1717185

Back

Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task

Journal article

Peer reviewed

Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task

Guoying Ni, Lu Zhang, Xiaodan Yang, Hejie Li, Bowei Ma, Shelley F Walton, Xiaolian Wu, Jianwei Yuan, Tianfang Wang and Xiao Song Liu

Human Vaccines & Immunotherapeutics, Vol.16(10), pp.2328-2332

2020

DOI: https://doi.org/10.1080/21645515.2020.1717185

PMCID: PMC7644214

PMID: 32159421

Files and links (1)

url

https://doi.org/10.1080/21645515.2020.1717185View

Published Version

Abstract

interleukin 10

PD-1

cancer immunotherapy

Interleukin 10 (IL-10) belongs to IL-10 family cytokines that are critical for maintaining the integrity of epithelial tissues, protecting pathogenic infection, and preventing excessive immune responses to damage self. Temporal IL-10 signaling blockade enhances vaccine-induced tumor regression by CD8 + T cells. IL-10, especially pegylated IL-10, mediates tumor regression by expanding tumor-infiltrating CD8 + T cells. Moreover, targeting IL-10 enhances immune checkpoint inhibitor mediated tumor regression. In the current paper, we will review recent advances in this area and discuss the complexity of IL-10 manipulation for cancer therapy.

Details

Title: Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task
Authors: Guoying Ni (Author) - University of the Sunshine Coast
Lu Zhang (Author) - First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, China
Xiaodan Yang (Author) - First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, China
Hejie Li (Author) - University of the Sunshine Coast
Bowei Ma (Author) - First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, China
Shelley F Walton (Author) - University of the Sunshine Coast
Xiaolian Wu (Author) - First People's Hospital of Foshan, China
Jianwei Yuan (Author) - First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, China
Tianfang Wang (Author) - University of the Sunshine Coast
Xiao Song Liu (Author) - First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, China
Publication details: Human Vaccines & Immunotherapeutics, Vol.16(10), pp.2328-2332
Publisher: Taylor & Francis Inc.
Date published: 2020
DOI: 10.1080/21645515.2020.1717185
ISSN: 2164-5515
PMID: 32159421; PMC7644214
Organisation Unit: School of Science and Engineering - Legacy; University of the Sunshine Coast, Queensland; GeneCology Research Centre - Legacy; School of Health and Sport Sciences - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
Language: English
Record Identifier: 99451413502621
Output Type: Journal article

Metrics

55 Record Views

45 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Biotechnology & Applied Microbiology; Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: SDGs from InCites